Study | Year | Design | Patient | Mean Age (years)a | Sex Male/Female | Sample size included | Follow-Up (months)a | Adverse eventsb | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PG | DG | PG | DG | PG | DG | PG | DG | PG | DG | |||||
Åkermark | 2013 | RCT | 76 | 48 (23–68) | 49 (25–71) | 10/25 | 10/31 | 32 | 41 | 34 (28–39) | 33 (28–42) | 5 | 6 | |
Xu | 2022 | RC | 20 | 50.00 ± 13.48 | 46.38 ± 12.93 | 2/10 | 3/5 | 12 | 8 | 27.08 ± 15.34 | 31.5 ± 8.35 | 0 | 2 | |
Faraj | 2010 | RC | 36 | 52.08 (31–67) | 2/34 | 20 | 22 | 18 | 12 | 6 | ||||
Åkermark | 2008 | RC | 125 | 52 (24–77) | 41/32 | 24/35 | 73 | 59 | 29 (24–46) | 37 (24–60) | 4 | 10 | ||
Wilson | 1995 | RC | 44 | NA | 3/41 | 21 | 59 | at least 1 year | 2 | 10 |